These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

520 related items for PubMed ID: 18332915

  • 1. Impact of pretransplant therapy in patients with newly diagnosed myeloma undergoing autologous SCT.
    Kumar SK, Dingli D, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Rajkumar SV, Litzow MR, Gertz MA.
    Bone Marrow Transplant; 2008 Jun; 41(12):1013-9. PubMed ID: 18332915
    [Abstract] [Full Text] [Related]

  • 2. Combination therapy with thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma not undergoing upfront autologous stem cell transplantation: a phase II trial.
    Dingli D, Rajkumar SV, Nowakowski GS, Gertz MA, Dispenzieri A, Lacy MQ, Hayman S, Fonseca R, Lust JA, Kyle RA, Greipp PR, Witzig TE.
    Haematologica; 2005 Dec; 90(12):1650-4. PubMed ID: 16330438
    [Abstract] [Full Text] [Related]

  • 3. Cyclophosphamide plus dexamethasone is an efficient initial treatment before high-dose melphalan and autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of a randomized comparison with vincristine, doxorubicin, and dexamethasone.
    Mellqvist UH, Lenhoff S, Johnsen HE, Hjorth M, Holmberg E, Juliusson G, Tangen JM, Westin J, Nordic Myeloma Study Group.
    Cancer; 2008 Jan 01; 112(1):129-35. PubMed ID: 17973267
    [Abstract] [Full Text] [Related]

  • 4. Long-term outcome of myeloablative allogeneic stem cell transplantation for multiple myeloma.
    Kuruvilla J, Shepherd JD, Sutherland HJ, Nevill TJ, Nitta J, Le A, Forrest DL, Hogge DE, Lavoie JC, Nantel SH, Toze CL, Smith CA, Barnett MJ, Song KW.
    Biol Blood Marrow Transplant; 2007 Aug 01; 13(8):925-31. PubMed ID: 17640596
    [Abstract] [Full Text] [Related]

  • 5. Retrospective comparison of bortezomib-containing regimens with vincristine-doxorubicin-dexamethasone (VAD) as induction treatment prior to autologous stem cell transplantation for multiple myeloma.
    Eom HS, Min CK, Cho BS, Lee S, Lee JW, Min WS, Kim CC, Kim M, Kim Y.
    Jpn J Clin Oncol; 2009 Jul 01; 39(7):449-55. PubMed ID: 19487425
    [Abstract] [Full Text] [Related]

  • 6. Complete remission status before autologous stem cell transplantation is an important prognostic factor in patients with multiple myeloma undergoing upfront single autologous transplantation.
    Kim JS, Kim K, Cheong JW, Min YH, Suh C, Kim H, Jo DY, Ryoo HM, Yoon SS, Lee JH, Korean Multiple Myeloma Working Party.
    Biol Blood Marrow Transplant; 2009 Apr 01; 15(4):463-70. PubMed ID: 19285634
    [Abstract] [Full Text] [Related]

  • 7. Post-transplant outcomes of induction therapy for myeloma: thalidomide and dexamethasone versus doxorubicin, vincristine, and dexamethasone prior to high-dose melphalan with autologous stem cell support.
    Vogl DT, Liu SV, Chong EA, Luger SM, Porter DL, Schuster SJ, Tsai DE, Perl A, Loren AW, Goldstein SC, Nasta SD, Andreadis C, Mangan PA, Hummel K, Siegel DL, Glatstein E, Stadtmauer EA.
    Am J Hematol; 2007 Dec 01; 82(12):1071-5. PubMed ID: 17696204
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Shifts in the therapeutic paradigm for patients newly diagnosed with multiple myeloma: maintenance therapy and overall survival.
    Palumbo A, Attal M, Roussel M.
    Clin Cancer Res; 2011 Mar 15; 17(6):1253-63. PubMed ID: 21411441
    [Abstract] [Full Text] [Related]

  • 13. Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure.
    Spencer A, Prince HM, Roberts AW, Prosser IW, Bradstock KF, Coyle L, Gill DS, Horvath N, Reynolds J, Kennedy N.
    J Clin Oncol; 2009 Apr 10; 27(11):1788-93. PubMed ID: 19273705
    [Abstract] [Full Text] [Related]

  • 14. Autologous stem cell transplantation in multiple myeloma: improved survival in nonsecretory multiple myeloma but lack of influence of age, status at transplant, previous treatment and conditioning regimen. A single-centre experience in 127 patients.
    Terpos E, Apperley JF, Samson D, Giles C, Crawley C, Kanfer E, Olavarria E, Goldman JM, Rahemtulla A.
    Bone Marrow Transplant; 2003 Feb 10; 31(3):163-70. PubMed ID: 12621476
    [Abstract] [Full Text] [Related]

  • 15. Sequential vincristine, adriamycin, dexamethasone (VAD) followed by bortezomib, thalidomide, dexamethasone (VTD) as induction, followed by high-dose therapy with autologous stem cell transplant and consolidation therapy with bortezomib for newly diagnosed multiple myeloma: results of a phase II trial.
    Kim HJ, Yoon SS, Lee DS, Sohn SK, Eom HS, Lee JL, Chung JS, Kim K, Suh C, Won JH, Kim JS, Park JS, Kang HJ, Seong CM, Kim CS, Lee SJ, Lee JH.
    Ann Hematol; 2012 Feb 10; 91(2):249-56. PubMed ID: 21789621
    [Abstract] [Full Text] [Related]

  • 16. Long-term outcome of autologous stem cell transplantation in light chain deposition disease.
    Lorenz EC, Gertz MA, Fervenza FC, Dispenzieri A, Lacy MQ, Hayman SR, Gastineau DA, Leung N.
    Nephrol Dial Transplant; 2008 Jun 10; 23(6):2052-7. PubMed ID: 18178602
    [Abstract] [Full Text] [Related]

  • 17. Short-term thalidomide incorporated into double autologous stem-cell transplantation improves outcomes in comparison with double autotransplantation for multiple myeloma.
    Cavo M, Di Raimondo F, Zamagni E, Patriarca F, Tacchetti P, Casulli AF, Volpe S, Perrone G, Ledda A, Ceccolini M, Califano C, Bigazzi C, Offidani M, Stefani P, Ballerini F, Fiacchini M, de Vivo A, Brioli A, Tosi P, Baccarani M.
    J Clin Oncol; 2009 Oct 20; 27(30):5001-7. PubMed ID: 19720903
    [Abstract] [Full Text] [Related]

  • 18. Induction therapy with vincristine, adriamycin, dexamethasone (VAD) and intermediate-dose melphalan (IDM) followed by autologous or allogeneic stem cell transplantation in newly diagnosed multiple myeloma.
    Lokhorst HM, Sonneveld P, Cornelissen JJ, Joosten P, van Marwijk Kooy M, Meinema J, Nieuwenhuis HK, van Oers MH, Richel DJ, Segeren CN, Veth G, Verdonck LF, Wijermans PW.
    Bone Marrow Transplant; 1999 Feb 20; 23(4):317-22. PubMed ID: 10100574
    [Abstract] [Full Text] [Related]

  • 19. Thalidomide as salvage therapy for VAD-refractory multiple myeloma prior to autologous PBSCT.
    Ahmad I, Islam T, Chanan-Khan A, Hahn T, Wentling D, Becker JL, McCarthy PL, Alam AR.
    Bone Marrow Transplant; 2002 Apr 20; 29(7):577-80. PubMed ID: 11979306
    [Abstract] [Full Text] [Related]

  • 20. [Efficacy of thalidomide combined dexamethasone on newly diagnosed multiple myeloma].
    Yuan ZG, Hou J, Wang DX, Fu WJ, Chen YB, Xi H.
    Ai Zheng; 2007 Dec 20; 26(12):1369-72. PubMed ID: 18076804
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.